Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C3 | P42330 | 9/20 | 0.51 |
| ▸ | CBR1 | P16152 | 3/20 | 0.51 |
| ▸ | AR | P10275 | 2/20 | 0.51 |
| ▸ | MAOB | P27338 | 5/20 | 0.50 |
| ▸ | MAOA | P21397 | 4/20 | 0.50 |
| ▸ | CASP3 | P42574 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 3/20 | 0.46 |
| ▸ | RAB9A | P51151 | 3/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | F12 | P00748 | 2/20 | 0.45 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL982902 | 0.88 | CASP3 (0.61) | MAOBCASP3NPC1RAB9ATP53 | |
| SCHEMBL978881 | 0.87 | MAOB (0.48) | AKR1C3CBR1ARMAOBMAOA | |
| SCHEMBL981176 | 0.87 | CASP3 (0.51) | AKR1C3CBR1ARMAOBMAOA | |
| SCHEMBL980408 | 0.86 | KMT2A (0.52) | AKR1C3CBR1ARMAOBMAOA | |
| SCHEMBL978163 | 0.85 | MAOB (0.52) | AKR1C3CBR1ARMAOBMAOA | |
| SCHEMBL978668 | 0.85 | CASP3 (0.53) | AKR1C3CBR1ARMAOBMAOA | |
| SCHEMBL980671 | 0.84 | MAPK1 (0.55) | AKR1C3CBR1ARMAOBMAOA | |
| SCHEMBL980848 | 0.82 | CASP3 (0.50) | AKR1C3CBR1ARMAOBMAOA | |
| SCHEMBL982797 | 0.82 | AKR1C3 (0.59) | AKR1C3CBR1ARMAOBMAOA | |
| SCHEMBL981025 | 0.81 | CASP3 (0.51) | AKR1C3CBR1ARMAOBMAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110021522-A1 | ACTIVATORS OF EXECUTIONER PROCASPASES 3, 6 AND 7 | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2011-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110021522-A1 | ACTIVATORS OF EXECUTIONER PROCASPASES 3, 6 AND 7 | CASP7, CASP3, CASP6 | AKR1C3 3154/4885CBR1 2963/4885AR 3534/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.